Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Papillomaviridae Clear all
Completed No phase listed Observational Accepts healthy volunteers

High-Risk HPV Infections in Women Aged 25 to 65

NCT00461877
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 27, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial

NCT07178301
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Computed Tomography, Nasopharyngeal Laryngoscopy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Chicago, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study

NCT04660331
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Communication Intervention, Communication Skills Training, Healthcare Activity, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

NCT00116675
View directory record Official record
Conditions
Warts
Interventions
Resiquimod
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
3 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Jonesboro, Arkansas • San Francisco, California • Longmont, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2007 · Synced Sep 27, 2026, 2:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

NCT06319963
View directory record Official record
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers

NCT00680147
View directory record Official record
Conditions
HPV
Interventions
brief informational intervention to promote HPV vaccine acceptance
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
11 Years and older
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls

NCT01254669
View directory record Official record
Conditions
Cervical Cancer
Interventions
BNI-brief Negotiated Interview
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
11 Years to 15 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 27, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

NCT05388773
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment, intensity-modulated radiation therapy, Cisplatin, Carboplatin
Procedure · Other · Radiation + 1 more
Lead sponsor
Heath Skinner
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831
View directory record Official record
Conditions
Common Wart
Interventions
Active, Vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 27, 2026, 2:53 AM EDT
Active, not recruiting Not applicable Interventional

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

NCT06611553
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 27, 2026, 2:53 AM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

NCT02280642
View directory record Official record
Conditions
Cervical Cancer, Genital Warts
Interventions
Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

NCT01492582
View directory record Official record
Conditions
Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review
Biological · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 26 Years
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

NCT02798419
View directory record Official record
Conditions
Common Warts
Interventions
DFD05 Cream, Active01 Cream
Drug
Lead sponsor
Dr. Reddys Laboratories, SA
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Hot Springs, Arkansas • Fremont, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510
View directory record Official record
Conditions
Common Wart
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
1 Year and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
46
States / cities
Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailoring of Vaccine-Focused Messages: Disease Salience

NCT03002324
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Baseline Survey, Current CDC Message, Cervical Cancer Message, Control Message, Post-Intervention Survey
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 27, 2026, 2:53 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

NCT03799445
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Posterior Tongue Squamous Cell Carcinoma, Soft Palate Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Tonsillar Squamous Cell Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial

NCT02535845
View directory record Official record
Conditions
Human Papillomavirus Vaccines
Interventions
Project Voice, HPV Informational Video
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Optimizing Application And Support Of Immunization Information Systems (OASIS)

NCT02010372
View directory record Official record
Conditions
Increase in Use of Immunization Registry, Increase in HPV Vaccination Rate
Interventions
Reminder Recall Report, Audit-Feedback/Immunization Forecasting Reports
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 27, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions
Gardasil, Survey
Biological · Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 26 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 27, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The SPOT-HPV Study

NCT05524025
View directory record Official record
Conditions
HPV Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Salivary TTMV-HPV DNA Test, Blood TTMV-HPV DNA Test
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 27, 2026, 2:53 AM EDT
Completed No phase listed Observational

County Level Correlates of HPV Vaccine Series Completion Among Children Ages 11-14 Years in Indiana

NCT04576962
View directory record Official record
Conditions
Human Papillomavirus Vaccination
Interventions
Immunization Information System Review
Other
Lead sponsor
Indiana University
Other
Eligibility
9 Years to 14 Years
Enrollment
122,152 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 27, 2026, 2:53 AM EDT
Completed Not applicable Interventional

The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia

NCT00653146
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Mindfulness-Based Stress Reduction, Healthy Lifestyles
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 27, 2026, 2:53 AM EDT